Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a global
prevalence estimated at approximately 25%. NAFLD is also the leading cause of liver …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Abstract Background and Aims In patients with NAFLD, those with type 2 diabetes mellitus
(DM) have a high risk of progression to HCC. However, the determinants of HCC risk in …

Introduction: The relationship between nonalcoholic fatty liver disease (NAFLD) and type 2
diabetes mellitus (T2DM) is complex and bidirectional. NAFLD increases the risk of incident …

Background and Aims The long‐term risk of disease for patients with nonalcoholic fatty liver
disease (NAFLD) in the absence of elevated enzymes is unclear. We conducted a …

Background Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly
proposed definition of fatty liver disease (FLD) independent of excessive alcohol …

Methods Using 2011–2018 National Health and Nutrition Examination Survey (NHANES)
data, a cross-sectional, stratified, multistage probability sample of the US population, we …

Background and Aims Statins have been proven to be cytotoxic to human
cholangiocarcinoma cells by inhibiting cell division and inducing apoptosis. We aimed to …

Background/aims Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease
(NAFLD) share pathophysiological mechanism. Metformin is a widely used first-line anti …

Objectives: To analyze the clinicopathological features and risk factors of Type-2 diabetes
mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD). Methods: The data …